Loading…

Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty

Abstract Background Although pain management affects rehabilitation, length of stay, and functional outcome, an optimized pain management protocol has yet to be standardized. Opioids are the primary agent used to control acute postoperative pain; however, they are associated with a wide range of sid...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of arthroplasty 2016-07, Vol.31 (7), p.1510-1515
Main Authors: Yu, Stephen W., MD, Szulc, Alessandra L., MA, Walton, Sharon L., MD, Davidovitch, Roy I., MD, Bosco, Joseph A., MD, Iorio, Richard, MD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23
cites cdi_FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23
container_end_page 1515
container_issue 7
container_start_page 1510
container_title The Journal of arthroplasty
container_volume 31
creator Yu, Stephen W., MD
Szulc, Alessandra L., MA
Walton, Sharon L., MD
Davidovitch, Roy I., MD
Bosco, Joseph A., MD
Iorio, Richard, MD
description Abstract Background Although pain management affects rehabilitation, length of stay, and functional outcome, an optimized pain management protocol has yet to be standardized. Opioids are the primary agent used to control acute postoperative pain; however, they are associated with a wide range of side effects. Liposomal bupivacaine (LB), a long-acting analgesic agent administered intraoperatively, has been introduced as a new modality to control pain for up to 72 hours after operation without affecting motor function. Methods Six hundred eighty-six primary total hip arthroplasty (THA) patients, who received the standard THA pain management protocol, were compared to a cohort of 586 primary THA patients, who were treated with an additional intraoperative injection of LB. All other pain management parameters and standard of care were identical. Statistical significance was set at P ≤ .05. Results Although patient-reported pain scores were statistically similar, the LB cohort demonstrated a significant decrease in total narcotic use ( P < .001), specifically up to postoperative day 2 ( P  = .016). Physical therapy milestones were significantly achieved to a greater degree ( P < .001) in the LB cohort. Operation time and hospital cost were unaffected ( P  = .072 and .811, respectively); however, the LB cohort exhibited a decrease in length of stay by 0.31 days ( P < .001) and improvement in discharge disposition to home ( P  = .017). Conclusion LB is a valuable adjunct to our THA pain management protocol, as we strive to achieve improved patient outcomes, reductions in length of stay, and enhanced quality of THA care.
doi_str_mv 10.1016/j.arth.2016.01.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1798722463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0883540316000644</els_id><sourcerecordid>1798722463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23</originalsourceid><addsrcrecordid>eNp9kU-LFDEQxYMo7rj6BTxIjl66rfzrzoAI46C7woALricPIZOuxow9nTZJD8y3N82se_DgpaoI7z1SvyLkNYOaAWveHWob88-al7kGVgPIJ2TFlOCVltA8JSvQWlRKgrgiL1I6ADCmlHxOrnijW660XJEfOz-FFI52oB_nyZ-ss35EahO1I910h3l0meZA70LKYcJosz8hvSsiug1jjmGgZbwPuQTc-oluyo9imAab8vkledbbIeGrh35Nvn_-dL-9rXZfb75sN7vKScZy1TLBO60kNgyVtEKrtmuQqb3Y94KvQWF5YrLX3V5Dqa53Wutegu5btu65uCZvL7lTDL9nTNkcfXI4DHbEMCfD2nVZl8tGFCm_SF0MKUXszRT90cazYWAWqOZgFqhmgWqAmQK1mN485M_7I3aPlr8Ui-D9RYBly5PHaJLzODrsfESXTRf8__M__GN3gx-9s8MvPGM6hDmOhZ9hJnED5tty1uWqrAGARkrxB_IsnM4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1798722463</pqid></control><display><type>article</type><title>Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty</title><source>Elsevier</source><creator>Yu, Stephen W., MD ; Szulc, Alessandra L., MA ; Walton, Sharon L., MD ; Davidovitch, Roy I., MD ; Bosco, Joseph A., MD ; Iorio, Richard, MD</creator><creatorcontrib>Yu, Stephen W., MD ; Szulc, Alessandra L., MA ; Walton, Sharon L., MD ; Davidovitch, Roy I., MD ; Bosco, Joseph A., MD ; Iorio, Richard, MD</creatorcontrib><description>Abstract Background Although pain management affects rehabilitation, length of stay, and functional outcome, an optimized pain management protocol has yet to be standardized. Opioids are the primary agent used to control acute postoperative pain; however, they are associated with a wide range of side effects. Liposomal bupivacaine (LB), a long-acting analgesic agent administered intraoperatively, has been introduced as a new modality to control pain for up to 72 hours after operation without affecting motor function. Methods Six hundred eighty-six primary total hip arthroplasty (THA) patients, who received the standard THA pain management protocol, were compared to a cohort of 586 primary THA patients, who were treated with an additional intraoperative injection of LB. All other pain management parameters and standard of care were identical. Statistical significance was set at P ≤ .05. Results Although patient-reported pain scores were statistically similar, the LB cohort demonstrated a significant decrease in total narcotic use ( P &lt; .001), specifically up to postoperative day 2 ( P  = .016). Physical therapy milestones were significantly achieved to a greater degree ( P &lt; .001) in the LB cohort. Operation time and hospital cost were unaffected ( P  = .072 and .811, respectively); however, the LB cohort exhibited a decrease in length of stay by 0.31 days ( P &lt; .001) and improvement in discharge disposition to home ( P  = .017). Conclusion LB is a valuable adjunct to our THA pain management protocol, as we strive to achieve improved patient outcomes, reductions in length of stay, and enhanced quality of THA care.</description><identifier>ISSN: 0883-5403</identifier><identifier>EISSN: 1532-8406</identifier><identifier>DOI: 10.1016/j.arth.2016.01.004</identifier><identifier>PMID: 26872584</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Anesthetics, Local - administration &amp; dosage ; Arthroplasty, Replacement, Hip ; Bupivacaine - administration &amp; dosage ; Female ; Humans ; Injections, Intra-Articular ; Intraoperative Care ; liposomal bupivacaine ; Liposomes - administration &amp; dosage ; Male ; Middle Aged ; narcotic usage ; Orthopedics ; pain control ; Pain Management ; Pain, Postoperative - drug therapy ; quality ; Retrospective Studies ; total hip arthroplasty</subject><ispartof>The Journal of arthroplasty, 2016-07, Vol.31 (7), p.1510-1515</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23</citedby><cites>FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23</cites><orcidid>0000-0002-0107-5771</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26872584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Stephen W., MD</creatorcontrib><creatorcontrib>Szulc, Alessandra L., MA</creatorcontrib><creatorcontrib>Walton, Sharon L., MD</creatorcontrib><creatorcontrib>Davidovitch, Roy I., MD</creatorcontrib><creatorcontrib>Bosco, Joseph A., MD</creatorcontrib><creatorcontrib>Iorio, Richard, MD</creatorcontrib><title>Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty</title><title>The Journal of arthroplasty</title><addtitle>J Arthroplasty</addtitle><description>Abstract Background Although pain management affects rehabilitation, length of stay, and functional outcome, an optimized pain management protocol has yet to be standardized. Opioids are the primary agent used to control acute postoperative pain; however, they are associated with a wide range of side effects. Liposomal bupivacaine (LB), a long-acting analgesic agent administered intraoperatively, has been introduced as a new modality to control pain for up to 72 hours after operation without affecting motor function. Methods Six hundred eighty-six primary total hip arthroplasty (THA) patients, who received the standard THA pain management protocol, were compared to a cohort of 586 primary THA patients, who were treated with an additional intraoperative injection of LB. All other pain management parameters and standard of care were identical. Statistical significance was set at P ≤ .05. Results Although patient-reported pain scores were statistically similar, the LB cohort demonstrated a significant decrease in total narcotic use ( P &lt; .001), specifically up to postoperative day 2 ( P  = .016). Physical therapy milestones were significantly achieved to a greater degree ( P &lt; .001) in the LB cohort. Operation time and hospital cost were unaffected ( P  = .072 and .811, respectively); however, the LB cohort exhibited a decrease in length of stay by 0.31 days ( P &lt; .001) and improvement in discharge disposition to home ( P  = .017). Conclusion LB is a valuable adjunct to our THA pain management protocol, as we strive to achieve improved patient outcomes, reductions in length of stay, and enhanced quality of THA care.</description><subject>Aged</subject><subject>Anesthetics, Local - administration &amp; dosage</subject><subject>Arthroplasty, Replacement, Hip</subject><subject>Bupivacaine - administration &amp; dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intra-Articular</subject><subject>Intraoperative Care</subject><subject>liposomal bupivacaine</subject><subject>Liposomes - administration &amp; dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>narcotic usage</subject><subject>Orthopedics</subject><subject>pain control</subject><subject>Pain Management</subject><subject>Pain, Postoperative - drug therapy</subject><subject>quality</subject><subject>Retrospective Studies</subject><subject>total hip arthroplasty</subject><issn>0883-5403</issn><issn>1532-8406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kU-LFDEQxYMo7rj6BTxIjl66rfzrzoAI46C7woALricPIZOuxow9nTZJD8y3N82se_DgpaoI7z1SvyLkNYOaAWveHWob88-al7kGVgPIJ2TFlOCVltA8JSvQWlRKgrgiL1I6ADCmlHxOrnijW660XJEfOz-FFI52oB_nyZ-ss35EahO1I910h3l0meZA70LKYcJosz8hvSsiug1jjmGgZbwPuQTc-oluyo9imAab8vkledbbIeGrh35Nvn_-dL-9rXZfb75sN7vKScZy1TLBO60kNgyVtEKrtmuQqb3Y94KvQWF5YrLX3V5Dqa53Wutegu5btu65uCZvL7lTDL9nTNkcfXI4DHbEMCfD2nVZl8tGFCm_SF0MKUXszRT90cazYWAWqOZgFqhmgWqAmQK1mN485M_7I3aPlr8Ui-D9RYBly5PHaJLzODrsfESXTRf8__M__GN3gx-9s8MvPGM6hDmOhZ9hJnED5tty1uWqrAGARkrxB_IsnM4</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Yu, Stephen W., MD</creator><creator>Szulc, Alessandra L., MA</creator><creator>Walton, Sharon L., MD</creator><creator>Davidovitch, Roy I., MD</creator><creator>Bosco, Joseph A., MD</creator><creator>Iorio, Richard, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0107-5771</orcidid></search><sort><creationdate>20160701</creationdate><title>Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty</title><author>Yu, Stephen W., MD ; Szulc, Alessandra L., MA ; Walton, Sharon L., MD ; Davidovitch, Roy I., MD ; Bosco, Joseph A., MD ; Iorio, Richard, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Anesthetics, Local - administration &amp; dosage</topic><topic>Arthroplasty, Replacement, Hip</topic><topic>Bupivacaine - administration &amp; dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intra-Articular</topic><topic>Intraoperative Care</topic><topic>liposomal bupivacaine</topic><topic>Liposomes - administration &amp; dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>narcotic usage</topic><topic>Orthopedics</topic><topic>pain control</topic><topic>Pain Management</topic><topic>Pain, Postoperative - drug therapy</topic><topic>quality</topic><topic>Retrospective Studies</topic><topic>total hip arthroplasty</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Stephen W., MD</creatorcontrib><creatorcontrib>Szulc, Alessandra L., MA</creatorcontrib><creatorcontrib>Walton, Sharon L., MD</creatorcontrib><creatorcontrib>Davidovitch, Roy I., MD</creatorcontrib><creatorcontrib>Bosco, Joseph A., MD</creatorcontrib><creatorcontrib>Iorio, Richard, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of arthroplasty</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Stephen W., MD</au><au>Szulc, Alessandra L., MA</au><au>Walton, Sharon L., MD</au><au>Davidovitch, Roy I., MD</au><au>Bosco, Joseph A., MD</au><au>Iorio, Richard, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty</atitle><jtitle>The Journal of arthroplasty</jtitle><addtitle>J Arthroplasty</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>31</volume><issue>7</issue><spage>1510</spage><epage>1515</epage><pages>1510-1515</pages><issn>0883-5403</issn><eissn>1532-8406</eissn><abstract>Abstract Background Although pain management affects rehabilitation, length of stay, and functional outcome, an optimized pain management protocol has yet to be standardized. Opioids are the primary agent used to control acute postoperative pain; however, they are associated with a wide range of side effects. Liposomal bupivacaine (LB), a long-acting analgesic agent administered intraoperatively, has been introduced as a new modality to control pain for up to 72 hours after operation without affecting motor function. Methods Six hundred eighty-six primary total hip arthroplasty (THA) patients, who received the standard THA pain management protocol, were compared to a cohort of 586 primary THA patients, who were treated with an additional intraoperative injection of LB. All other pain management parameters and standard of care were identical. Statistical significance was set at P ≤ .05. Results Although patient-reported pain scores were statistically similar, the LB cohort demonstrated a significant decrease in total narcotic use ( P &lt; .001), specifically up to postoperative day 2 ( P  = .016). Physical therapy milestones were significantly achieved to a greater degree ( P &lt; .001) in the LB cohort. Operation time and hospital cost were unaffected ( P  = .072 and .811, respectively); however, the LB cohort exhibited a decrease in length of stay by 0.31 days ( P &lt; .001) and improvement in discharge disposition to home ( P  = .017). Conclusion LB is a valuable adjunct to our THA pain management protocol, as we strive to achieve improved patient outcomes, reductions in length of stay, and enhanced quality of THA care.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26872584</pmid><doi>10.1016/j.arth.2016.01.004</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0107-5771</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0883-5403
ispartof The Journal of arthroplasty, 2016-07, Vol.31 (7), p.1510-1515
issn 0883-5403
1532-8406
language eng
recordid cdi_proquest_miscellaneous_1798722463
source Elsevier
subjects Aged
Anesthetics, Local - administration & dosage
Arthroplasty, Replacement, Hip
Bupivacaine - administration & dosage
Female
Humans
Injections, Intra-Articular
Intraoperative Care
liposomal bupivacaine
Liposomes - administration & dosage
Male
Middle Aged
narcotic usage
Orthopedics
pain control
Pain Management
Pain, Postoperative - drug therapy
quality
Retrospective Studies
total hip arthroplasty
title Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A15%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liposomal%20Bupivacaine%20as%20an%20Adjunct%20to%20Postoperative%20Pain%20Control%20in%20Total%20Hip%20Arthroplasty&rft.jtitle=The%20Journal%20of%20arthroplasty&rft.au=Yu,%20Stephen%20W.,%20MD&rft.date=2016-07-01&rft.volume=31&rft.issue=7&rft.spage=1510&rft.epage=1515&rft.pages=1510-1515&rft.issn=0883-5403&rft.eissn=1532-8406&rft_id=info:doi/10.1016/j.arth.2016.01.004&rft_dat=%3Cproquest_cross%3E1798722463%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-7132d854e61e54a3857d6e15b3bf32905e38514f8db80f8dcfc888f408f719f23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1798722463&rft_id=info:pmid/26872584&rfr_iscdi=true